Prednisolone

Generic Name: Prednisolone

Brand Names: Millipred Dp 6 Day

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₈O_₅

CAS Number: 50-24-8

Unique Ingredient Identifier: 9PHQ9Y1OLM

Background: Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

Prednisolone was granted FDA approval on 21 June 1955.

Indication: Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Contact Dermatitis, Allergic Skin Reaction, Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonia, Aspiration Pneumonitis, Atopic Dermatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Burns, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Corneal injuries, Corneal ulceration, Crohn's Disease (CD), Cyclitis, Dermatomyositis (DM), Dermatosis of the Ear Canal, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Exacerbation of COPD, Exacerbation of asthma, Eye inflammation caused by Cataract Surgery, Eye inflammation caused by Infection, Fissure;Anal, Herpes Zoster Keratitis, Hot Water Burns (Scalds), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Inflamed External Hemorrhoid, Inflamed Hemorrhoids, Internal, Inflammatory Reaction caused by susceptible Bacterial Infections, Iridocyclitis, Iritis, Itching caused by susceptible Bacterial Infections, Keratitis, Loeffler's syndrome, Lymphoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Otic Eczema, Pemphigus, Perennial Allergic Rhinitis (PAR), Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Posterior Uveitis, Posttraumatic Osteoarthritis, Proctitis, Proteinuria, Pruritus, Pruritus Ani, Psoriatic Arthritis, Pulmonary Tuberculosis (TB), Pure Red Cell Aplasia, Rash, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Seasonal Allergic Rhinitis, Secondary Adrenal Insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Asthma, Sjogren's Syndrome (SS), Stevens-Johnson Syndrome, Superficial punctate keratitis, Synovitis, Systemic Lupus Erythematosus, Transplanted Organ Rejection, Trichinosis, Tuberculosis (TB), Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Anal eczema, Bacterial skin infections, Exfoliative erythroderma, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Primary adrenocoritical insufficiency, Severe Psoriasis, Severe Seborrhoeic dermatitis, Severe alcoholic liver disease, Steroid-responsive inflammation of the eye, Subacute Bursitis, Susceptible Bacterial Infections, Symptomatic Sarcoidosis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: -

Clinical Trials

Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: imatinib
Drug: cyclophosphamide
Drug: daunorubicin
Drug: vincristine
Drug: prednisolone
Drug: methotrexate
Drug: cytarabine
Drug: dexamethasone

First Posted Date: 2005-08-15

Last Posted Date: 2008-11-14

Lead Sponsor: Japan Adult Leukemia Study Group

Target Recruit Count: 100

Registration Number: NCT00130195

Locations: 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma

Phase 3

Completed

Conditions: Follicular Lymphoma

Interventions: Drug: Cyclophosphamide
Radiation: Radiotherapy
Drug: Vincristine
Drug: Prednisolone
Drug: Rituximab

First Posted Date: 2005-06-24

Last Posted Date: 2022-11-18

Lead Sponsor: Trans Tasman Radiation Oncology Group

Target Recruit Count: 150

Registration Number: NCT00115700

Locations: 🇳🇿
Wellington Hospital, Wellington, New Zealand
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺
The Canberra Hospital, Garran, Australian Capital Territory, Australia

and more 18 locations

Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2004-05-24

Last Posted Date: 2013-08-07

Lead Sponsor: Cancer Research Campaign Clinical Trials Centre

Target Recruit Count: 200

Registration Number: NCT00002576

Locations: 🇬🇧
Nottingham City Hospital NHS Trust, Nottingham, England, United Kingdom

Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2004-05-20

Last Posted Date: 2013-12-19

Lead Sponsor: United Kingdom Children's Cancer Study Group

Target Recruit Count: 100

Registration Number: NCT00003423

Locations: 🇬🇧
Hospital for Sick Children NHS Trust, London, England, United Kingdom

Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease

Phase 3

Conditions: Lymphoma

First Posted Date: 2004-04-06

Last Posted Date: 2013-12-04

Lead Sponsor: Medical Research Council

Target Recruit Count: 400

Registration Number: NCT00002987

Locations: 🇿🇦
Groote Schuur Hospital, Cape Town, Cape Town, South Africa
🇬🇧
Royal Preston Hospital, Preston, United Kingdom
🇬🇧
Bristol Royal Hospital for Sick Children, Bristol, England, United Kingdom

and more 15 locations

Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2004-03-12

Last Posted Date: 2013-12-04

Lead Sponsor: Medical Research Council

Target Recruit Count: 800

Registration Number: NCT00003421

Locations: 🇬🇧
Weston Park Hospital, Sheffield, England, United Kingdom
🇬🇧
St. James's Hospital, Leeds, England, United Kingdom

A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: bleomycin sulfate
Drug: cyclophosphamide
Drug: etoposide
Drug: mitoxantrone hydrochloride
Drug: prednisolone
Drug: procarbazine hydrochloride
Drug: vinblastine sulfate

First Posted Date: 2004-03-09

Last Posted Date: 2017-03-30

Lead Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust

Target Recruit Count: 175

Registration Number: NCT00079105

Locations: 🇬🇧
Royal United Hospital, Bath, England, United Kingdom
🇬🇧
Kent and Canterbury Hospital, Canterbury, England, United Kingdom
🇬🇧
Saint Richards Hospital, Chichester, England, United Kingdom

and more 51 locations